KLK6 and KLK13 predict tumor recurrence in epithelial ovarian carcinoma
| Autor: | Catherine Popadiuk, Maria Mathews, Jules J. E. Doré, George M. Yousef, A Prizada, Nicole White |
|---|---|
| Rok vydání: | 2009 |
| Předmět: |
Oncology
human kallikrein-related peptidase 6 Cancer Research medicine.medical_specialty Pathology Biology medicine.disease_cause 03 medical and health sciences Ovarian tumor 0302 clinical medicine ovarian carcinogenesis Internal medicine Gene expression medicine Humans Neoplasms Glandular and Epithelial RNA Messenger Survival analysis 030304 developmental biology Ovarian Neoplasms 0303 health sciences biomarkers Cancer KLK6 Prognosis medicine.disease Immunohistochemistry 3. Good health ovarian cancer 030220 oncology & carcinogenesis Regression Analysis Female Kallikreins Neoplasm Recurrence Local Translational Therapeutics Ovarian cancer Carcinogenesis human kallikrein-related peptidase 13 |
| Zdroj: | British Journal of Cancer |
| ISSN: | 1532-1827 0007-0920 |
| DOI: | 10.1038/sj.bjc.6605280 |
| Popis: | Background: The human kallikrein-related peptidase family consists of 15 genes. Twelve of these genes are overexpressed in ovarian cancer and may represent potential markers for diagnosis, prognosis, and/or response to treatment. The aim of this study was to determine the prognostic significance of kallikrein-related peptidase 6 (KLK6) and kallikrein-related peptidase 13 (KLK13) in epithelial ovarian cancer by quantifying gene expression levels with tumour pathology and patient survival data. Methods: Total RNA was isolated from 106 patients diagnosed with primary ovarian cancer, as well as 8 normal ovary controls. Samples were analysed by quantitative real-time PCR for KLK6 and KLK13 expression. Correlation between kallikrein gene expression and clinical characteristics was evaluated with the χ2-test. Survival analysis was performed using Kaplan–Meier and Cox proportional hazards regression models. Results: Expression levels of both KLK6 and KLK13 mRNA were significantly increased in invasive cancers relative to normal ovaries (P=0.002 and 0.039 respectively). High KLK6 and KLK13 expression was an indicator of poor prognosis, with patients having a shorter recurrence-free survival (P=0.002 and 0.027 respectively). High KLK6 expression was also significantly associated with lower overall survival (P=0.011). When subjected to multivariate analysis, patients with either high KLK6 or KLK13 were 3- and 2.2-fold, respectively, more likely to have a recurrence than patients with low kallikrein expression. Conclusion: These data show increased mRNA expression of KLK6 and KLK13 in ovarian cancer compared to normal ovarian tissues. High KLK6 or KLK13 expression in primary ovarian tumours can significantly predict prognosis in terms of recurrence-free survival and overall survival. In all, this study shows KLK6 and KLK13 as potential biomarkers and may be therapeutic targets for treatment of ovarian cancer. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|